Hellen C Barsosio
Overview
Explore the profile of Hellen C Barsosio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bokop C, Dhar N, Izu A, Ali M, Akaba G, Barsosio H, et al.
Int J Infect Dis
. 2025 Mar;
:107882.
PMID: 40081737
Objectives: To investigate the transplacental acquisition of measles IgG in newborn at delivery in Bangladesh, Bhutan, India, Ethiopia, Mozambique, Kenya, Nigeria, Mali, and South Africa. Methods: Archived cord serum, from...
2.
Gore-Langton G, Madanitsa M, Barsosio H, Minja D, Mosha J, Kavishe R, et al.
BMJ Public Health
. 2025 Feb;
2(2):e000501.
PMID: 40018559
Objectives: Malaria and curable sexually transmitted and reproductive tract infections (STIs/RTIs) are associated with adverse pregnancy outcomes. This study reports the prevalence and risk factors of curable STIs/RTIs, STI/RTI co-infection...
3.
Pingray V, Klein K, Alonso J, Belizan M, Babinska M, Alger J, et al.
EClinicalMedicine
. 2025 Feb;
80:103025.
PMID: 39896875
Background: Disease outbreaks significantly affect maternal and neonatal health. Variability in reporting health outcomes hinder evidence generation. We aimed to develop a core outcome set (COS) for maternal and neonatal...
4.
Roh M, Gutman J, Murphy M, Hill J, Madanitsa M, Kakuru A, et al.
medRxiv
. 2024 Dec;
PMID: 39649586
Background: High-grade resistance to sulfadoxine-pyrimethamine in East and Southern Africa has prompted numerous trials evaluating intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine as an alternative to sulfadoxine-pyrimethamine. Methods: We...
5.
Hoyt J, Barsosio H, Odero I, Omondi B, Achieng F, Kariuki S, et al.
Malar J
. 2024 Nov;
23(1):364.
PMID: 39614335
Background: Increasing resistance to sulfadoxine-pyrimethamine (SP) threatens the effectiveness of intermittent preventive treatment (IPTp) to prevent malaria in pregnancy. Dihydroartemisinin-piperaquine (DP) is the most promising candidate to emerge from clinical...
6.
El Gaaloul M, Tchouatieu A, Kayentao K, Campo B, Buffet B, Ramachandruni H, et al.
Malar J
. 2024 Nov;
23(1):363.
PMID: 39614327
No abstract available.
7.
El Gaaloul M, Tchouatieu A, Kayentao K, Campo B, Buffet B, Ramachandruni H, et al.
Malar J
. 2024 Oct;
23(1):315.
PMID: 39425110
Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector...
8.
Barsosio H, Webster J, Omiti F, KOloo A, Odero I, Ojuok M, et al.
Lancet Glob Health
. 2024 Sep;
12(10):e1660-e1672.
PMID: 39304238
Background: High-level resistance to sulfadoxine-pyrimethamine threatens the efficacy of WHO-recommended intermittent preventive treatment in pregnancy (IPTp) with single-dose sulfadoxine-pyrimethamine to prevent malaria. Monthly IPTp with dihydroartemisinin-piperaquine, a 3-day regimen, is...
9.
Alhassan Y, Otiso L, Okoth L, Murray L, Hemingway C, Lewis J, et al.
BMC Pregnancy Childbirth
. 2024 Mar;
24(1):224.
PMID: 38539129
Background: Early attendance at antenatal care (ANC), coupled with good-quality care, is essential for improving maternal and child health outcomes. However, achieving these outcomes in sub-Saharan Africa remains a challenge....
10.
Barsosio H, Madanitsa M, Ondieki E, Dodd J, Onyango E, Otieno K, et al.
Lancet
. 2024 Jan;
403(10424):365-378.
PMID: 38224710
Background: The efficacy of daily co-trimoxazole, an antifolate used for malaria chemoprevention in pregnant women living with HIV, is threatened by cross-resistance of Plasmodium falciparum to the antifolate sulfadoxine-pyrimethamine. We...